196 studies found for:
scleroderma
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 21 | Recruiting |
SCOT Scleroderma Treatment Alternative Registry (STAR Registry)
|
||||
| 22 | Completed |
Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis
|
||||
| 23 | Unknown † |
Scleroderma Registry
|
||||
| 24 | Enrolling by invitation |
Finger Hardness Measure in Scleroderma
|
||||
| 25 | Unknown † |
High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
|
||||
| 26 | Completed |
A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
|
||||
| 27 | Terminated |
Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
|
||||
| 28 | Recruiting |
Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
|
||||
| 29 | Terminated |
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
|
||||
| 30 | Recruiting |
Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
|
||||
| 31 | Active, not recruiting |
Scleroderma: Cyclophosphamide or Transplantation (SCOT)
|
||||
| 32 | Unknown † |
Influenza Vaccination in Patients With Scleroderma
|
||||
| 33 | Recruiting |
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
|
||||
| 34 | Completed |
Oral Type I Collagen for Relieving Scleroderma
|
||||
| 35 | Completed |
Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Scleroderma Patients
|
||||
| 36 | Recruiting |
Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough
|
||||
| 37 | Not yet recruiting |
Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension
|
||||
| 38 |
Terminated
Has Results |
Placebo Controlled Trial of Bosentan in Scleroderma Patients
|
||||
| 39 | Completed |
Premature Coronary Atherosclerosis in Scleroderma
|
||||
| 40 | Recruiting |
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
|
† Indicates status has not been verified in more than two years

